

NEWS RELEASE**ACROMECC'S IPO ATTRACTS STRONG INVESTOR DEMAND**

- ***27,000,000 New Shares 5.3 times subscribed***
- ***Commencement of trading expected to be at 9.00 a.m. on 18 April 2016***

Singapore, 15 April 2016 – Acromec Limited (“**Acromec**”, and together with its subsidiary, the “**Group**”), an established specialist engineering services provider in the field of controlled environments, received strong interest from investors for its initial public offering (“**IPO**” or “**Invitation**”) of 27,000,000 New Shares at S\$0.22 per New Share, in conjunction with its proposed listing on the Catalist Board of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”).

SAC Capital Private Limited (“**SAC Capital**”) is the Sponsor, Issue Manager, Underwriter and Placement Agent in connection with the IPO and will be Acromec’s continuing sponsor following its listing on Catalist.

As at the close of the Invitation at 12.00 noon on 14 April 2015, 1,209 valid applications were received for the 1,500,000 Offer Shares available to the public for subscription. In total, these applicants applied for an aggregate of 117,280,100 Offer Shares, with application monies received amounting to approximately S\$25.8 million.

Based on the total of 27,000,000 New Shares and the total valid applications received amounting to 142,604,100 New Shares (comprising valid applications received for 1,500,000 Offer Shares and 25,500,000 Placement Shares), the Invitation was approximately 5.3 times subscribed.

Commenting on the strong response for Acromec's IPO, Mr. Lim Say Chin, Executive Chairman and Managing Director of Acromec, said: "We are deeply encouraged by the strong investor support we have received for our IPO. This is a clear demonstration of the confidence that the investment community has in Acromec's proven track record and promising prospects in serving the growing healthcare, biomedical, and research and academia sectors."

"With our new listing status, we are well-positioned to further strengthen and grow our business in Singapore and the region. We embrace the challenge of elevating Acromec to its next level of growth and look forward to enhancing value for all our shareholders."

Net proceeds of approximately S\$4.5 million were raised from the Invitation. Acromec intends to utilise approximately S\$3.5 million as working capital to expand its business operations through securing more projects and projects of a larger scale, and the remaining S\$1.0 million for expansion through acquisitions, joint ventures and/or strategic alliances and venturing into new geographical markets.

Acromec's post-Invitation market capitalisation will be approximately S\$26.5 million based on the issue price of S\$0.22.

The listing and trading of Acromec's shares are expected to commence on a "ready" basis at 9.00 a.m. on 18 April 2016 under the stock code 1CH1.

About Acromec Limited (SGX Stock Code: 1CH1)

Acromec is an established specialist engineering services provider with 20 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

Acromec's business is divided into two main business segments: (i) Engineering, procurement and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure.

The Group mainly serves the healthcare, biomedical, research and academia, and electronics sectors. Acromec counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies. Some of the Group's customers include the National University of Singapore, Singapore General Hospital, A*Star, P&G and Johnson Matthey Singapore Private Limited.

For more information, please visit www.acromec.com.

ISSUED ON BEHALF OF : Acromec Limited
BY : Citigate Dewe Rogerson, i.MAGE Pte Ltd
55 Market Street
#02-01
SINGAPORE 048941
CONTACT : Mr Winston Choo / Ms Melissa Chia
at telephone
DURING OFFICE HOURS : 6534-5122 (Office)
AFTER OFFICE HOURS : 9068-2099 / 9770-1179 (Handphone)
EMAIL : winston.choo@citigatedrimage.com
melissa.chia@citigatedrimage.com

15 April 2016

Important Notice

*This news release and any accompanying material (the “**News Release**”) is for information purposes only, without regard to the objectives, financial situation or needs of any specific persons. Accordingly, no reliance whatsoever should be placed upon the information set out herein.*

*This News Release does not constitute or form any part of an offer of, or invitation or solicitation to subscribe for any securities nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information in this News Release is based on information found in the offer document of Acromec Limited dated 6 April 2016 (the “**Offer Document**”) that has been registered by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) acting as agent on behalf of the Monetary Authority of Singapore. Words and expressions, unless otherwise defined in this News Release, shall bear the same meanings assigned to them in the Offer Document.*

This News Release does not purport to be complete and is qualified in its entirety by, and should be read in conjunction with, the full text of the Offer Document, including but not limited to the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” of the Offer Document. The information contained in this News Release should not be relied on as any representation or warranty by Acromec Limited.

This News Release includes forward-looking statements provided with respect to the anticipated future performance of Acromec Limited. Such forward-looking statements reflect various assumptions concerning the future performance of Acromec Limited. Accordingly, there can be no assurance that such projections and forward-looking statements will be realised. The actual results may vary from the anticipated results and such variation may be material. No representations or warranties are made as to the accuracy or reasonableness of such assumptions or the forward-looking statements based thereon.

*This news release has been prepared by Acromec Limited (the “**Company**”) and its contents have been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “**Sponsor**”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “**Exchange**”). The Sponsor has not independently verified the contents of this news release.*

This news release has not been examined or approved by the Exchange. The Sponsor and the Exchange assume no responsibility for the contents of this news release, including the correctness of any of the statements or opinions made or reports contained in this news release.

The contact person for the Sponsor is Mr. Bernard Lim (Telephone: 65-6221 5590) at 1 Robinson Road, #21-02 AIA Tower, Singapore 048542.